Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Esperion Therapeutics, Inc.
Last earnings -11.2% on 2026-03-10
Revenue grew 21.3% YoY; but unprofitable (net margin -5.6%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Esperion Therapeutics, Inc. shows $403M in FY2025 revenue (+21.3% YoY), a -5.6% net margin, and 7.5% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001434868, latest 10-Q filed 2026-05-08) · EODHD · rules-based read · as of 6/18/2026, 5:36:37 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $78.4M | $75.5M | $116M | $332M | $403M |
| Gross profit | — | — | — | — | — |
| Operating income | -$227M | -$180M | -$156M | $54.4M | $60.3M |
| Net income | -$269M | -$234M | -$209M | -$51.7M | -$22.7M |
| Diluted EPS | -$9.31 | -$3.52 | -$2.03 | -$0.28 | -$0.11 |
| Net margin | -343.0% | -309.6% | -179.9% | -15.6% | -5.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
| 2026-05-28 | THOMPSON JOHN CRAIG Director | Award | 79.9K | |
| 2026-05-28 | Shepard Jay Director | Award | 79.9K | |
| 2026-05-28 | Hoffman Robert E. Director | Award | 79.9K | |
| 2026-05-28 | Fischer Seth H. Z. Director | Award | 79.9K | |
| 2026-05-28 | CARROLL J MARTIN Director | Award | 79.9K | |
| 2026-03-17 | Looker Benjamin Chief Legal Officer | Sell | 5.71K @ $2.70 | $15.4K |
| 2026-03-17 | Koenig Sheldon L. President and CEO | Sell | 25.6K @ $2.72 | $69.5K |
| 2026-03-17 | Halladay Benjamin Chief Financial Officer | Sell | 6.42K @ $2.71 | $17.4K |